MedTrace Logo

A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

NCT00052039 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2007-11-06

No results posted yet for this study

Summary

Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.

Conditions

Interventions

DRUG

interferon-gamma 1b

This study was terminated prior to enrollment.

DRUG

azathioprine

This study was terminated prior to enrollment.

Sponsors & Collaborators

  • InterMune

    lead INDUSTRY

Principal Investigators

  • Steven Porter, MD · InterMune

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Completion
2002-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00052039 on ClinicalTrials.gov